Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany

INTRODUCTION: In Germany, a 23-valent polysaccharide pneumococcal vaccine (PPSV23) is recommended for elderly (60+) and patients 16+ with chronic diseases not associated with immune suppression. For all other patients at risk, sequential immunization with a 13-valent pneumococcal conjugate vaccine (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuchenbecker, Ulrike, Chase, Daniela, Reichert, Anika, Schiffner-Rohe, Julia, Atwood, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967715/
https://www.ncbi.nlm.nih.gov/pubmed/29795647
http://dx.doi.org/10.1371/journal.pone.0197905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967715/
https://www.ncbi.nlm.nih.gov/pubmed/29795647
http://dx.doi.org/10.1371/journal.pone.0197905

Ejemplares similares